Blackstone Weighs Sale Of Japanese Pharma Firm Alinamin: Report
Portfolio Pulse from Akanksha Bakshi
Blackstone Inc. (NYSE:BX) is considering selling its Japanese consumer healthcare firm Alinamin Pharmaceutical Co., which could be valued at approximately ¥300 billion ($1.9 billion). The sale is attracting interest from CVC Capital Partners, EQT AB (OTC:EQBBF), and MBK Partners. Other possibilities include an initial public offering. Blackstone acquired Alinamin from Takeda Pharmaceutical Company Limited (NYSE:TAK) in 2021 for ¥242 billion.
June 03, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Takeda Pharmaceutical previously sold Alinamin to Blackstone in 2021. The potential sale of Alinamin by Blackstone does not directly impact Takeda but highlights the ongoing asset optimization strategies in the industry.
While the sale of Alinamin by Blackstone does not directly impact Takeda, it underscores the broader trend of asset optimization in the pharmaceutical industry.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 50
POSITIVE IMPACT
Blackstone is considering selling Alinamin Pharmaceutical Co., which could be valued at approximately $1.9 billion. This move is part of Blackstone's strategy to optimize its portfolio.
The potential sale of Alinamin could positively impact Blackstone's stock as it aligns with the company's strategy to optimize its portfolio and could result in a significant cash inflow.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100